Traders expect Nifty to touch 9,600-9,650
Nifty rollovers to the June series stood at 74 per cent, higher than the three-month average of 69 per cent.

The May series was the worst for the pharma sector since November 2015 derivatives series. Nifty Pharma index tanked 9 per cent due to weaker-than-expected March quarter results from Lupin and Sun Pharma's arm Taro, and continued worries over pricing pressures in the US. "It is just the start of how bad it is going to be.
Just like IT, the industry will have to reinvent itself," said Andrew Holland, CEO of Avendus Capital-Alternate Strategies. Rollovers were strong in the auto sector with higher roll cost suggesting further gains in the June series, while PSU banks saw a fall in roll cost, indicating that their underperformance will continue.
Download ET Markets APP